Moreover, the anti-tumor effects of both drugs are derived from different mechanisms of action; abiraterone inhibits androgen synthesis at non-gonadal sites (adrenal gland and intratumorally) to reduce androgens to below castrate concentrations, while enzalutamide, an anti-androgen, directly binds androgen receptors to inhibit androgen receptor nuclear translocation [17]. This evidence concerns the gene AR and neoplasm.